96 related articles for article (PubMed ID: 18825549)
1. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.
Larance B; Degenhardt L; Copeland J; Dillon P
Drug Alcohol Rev; 2008 Nov; 27(6):679-86. PubMed ID: 18825549
[TBL] [Abstract][Full Text] [Related]
2. Across the spectrum of legality: The market activities of influencers specialized in steroids and other performance and image enhancing drugs.
Paoli L; Joseph Cox LT
Int J Drug Policy; 2024 Jan; 123():104246. PubMed ID: 37979285
[TBL] [Abstract][Full Text] [Related]
3. Associations between injection risk and community disadvantage among suburban injection drug users in southwestern Connecticut, USA.
Heimer R; Barbour R; Palacios WR; Nichols LG; Grau LE
AIDS Behav; 2014 Mar; 18(3):452-63. PubMed ID: 23921583
[TBL] [Abstract][Full Text] [Related]
4. Is the use of performance and image enhancing drugs (PIEDs) in women an issue of concern? The findings from a stakeholder consultation.
Dunn M; Piatkowski TM; Robertson J; Lamon S
J Sci Med Sport; 2023 Nov; 26(11):574-579. PubMed ID: 37684155
[TBL] [Abstract][Full Text] [Related]
5. Men, bodywork, health and the potentiality of performance and image-enhancing drugs.
Dowsett GW; Duncan D; Waling A; Angelides S; Nourse G
Health Sociol Rev; 2023 Nov; 32(3):341-356. PubMed ID: 36577038
[TBL] [Abstract][Full Text] [Related]
6. Transition to injecting drug use in Iran: A systematic review of qualitative and quantitative evidence.
Rahimi-Movaghar A; Amin-Esmaeili M; Shadloo B; Noroozi A; Malekinejad M
Int J Drug Policy; 2015 Sep; 26(9):808-19. PubMed ID: 26210009
[TBL] [Abstract][Full Text] [Related]
7. Masculine enhancement as health or pathology: gender and optimisation discourses in health promotion materials on performance and image-enhancing drugs (PIEDs).
Nourse G; Fraser S; Moore D
Health Sociol Rev; 2024 Jan; ():1-17. PubMed ID: 38286142
[TBL] [Abstract][Full Text] [Related]
8. "Research chemicals": tryptamine and phenethylamine use among high-risk youth.
Sanders B; Lankenau SE; Bloom JJ; Hathazi D
Subst Use Misuse; 2008; 43(3-4):389-402. PubMed ID: 18365939
[TBL] [Abstract][Full Text] [Related]
9. Investigating the methods and characteristics of the trafficking of performance and image enhancing drugs in Australia.
Dunn M; Bright D; Fletcher P
Drug Alcohol Rev; 2024 Jan; 43(1):278-282. PubMed ID: 37718272
[TBL] [Abstract][Full Text] [Related]
10. 'Insulin is super dangerous if you don't know what you're doing': Situating the risks of insulin within the image and performance enhancing drug community.
Piatkowski T; Cox LTJ
Drug Alcohol Rev; 2024 Apr; ():. PubMed ID: 38665042
[TBL] [Abstract][Full Text] [Related]
11. Injection drug use in an affluent beachside community in Sydney: An exploratory qualitative study.
Dertadian GC; Caruana T; Maher L
Drug Alcohol Rev; 2023 Mar; 42(3):544-554. PubMed ID: 36539306
[TBL] [Abstract][Full Text] [Related]
12. Exploring Anabolic Androgenic Steroid Use Among Cisgender Gay, Bisexual, and Queer Men.
Kutscher E; Arshed A; Greene RE; Kladney M
JAMA Netw Open; 2024 May; 7(5):e2411088. PubMed ID: 38743422
[TBL] [Abstract][Full Text] [Related]
13. Analysis of four syringe dispensing machine point-of-access data 2017-2020 in Melbourne, Australia: machine utilisation and client demographics.
Kerr P; Cossar RD; Livingston M; Jacka D; Dietze P; O'Keefe D
Harm Reduct J; 2022 Dec; 19(1):144. PubMed ID: 36544124
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis.
Amaral JMX; Kimergård A; Deluca P
BMJ Open; 2022 Jul; 12(7):e056445. PubMed ID: 35788077
[TBL] [Abstract][Full Text] [Related]
15. Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network.
McVeigh J; Hearne E; Boardley I; Bates G; Hope V; Ralphs R; Van Hout MC
Harm Reduct J; 2021 Oct; 18(1):107. PubMed ID: 34657627
[TBL] [Abstract][Full Text] [Related]
16. Motivators of Indiscriminate and Unsafe Supplement Use among Young Australians.
Campbell A; Carins J; Rundle-Thiele S; Deshpande S; Baker B
Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639275
[TBL] [Abstract][Full Text] [Related]
17. Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access.
Harvey O; Keen S; Parrish M; van Teijlingen E
BMC Public Health; 2019 Jul; 19(1):1024. PubMed ID: 31366349
[TBL] [Abstract][Full Text] [Related]
18. Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.
Anderson LJ; Tamayose JM; Garcia JM
Mol Cell Endocrinol; 2018 Mar; 464():65-74. PubMed ID: 28606865
[TBL] [Abstract][Full Text] [Related]
19. Recruitment to doping and help-seeking behavior of eight female AAS users.
Börjesson A; Gårevik N; Dahl ML; Rane A; Ekström L
Subst Abuse Treat Prev Policy; 2016 Mar; 11():11. PubMed ID: 26945991
[TBL] [Abstract][Full Text] [Related]
20. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis.
Sagoe D; McVeigh J; Bjørnebekk A; Essilfie MS; Andreassen CS; Pallesen S
Subst Abuse Treat Prev Policy; 2015 Mar; 10():12. PubMed ID: 25888931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
